Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BeOne Medicines (NAS:ONC) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
BeOne Medicines Forward PE Ratio Related Terms
BeOne Medicines Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for BeOne Medicines's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BeOne Medicines Forward PE Ratio Chart
BeOne Medicines Annual Data
Trend
2025-12
Forward PE Ratio
46.39
BeOne Medicines Quarterly Data
2024-09
2025-09
2025-12
2026-03
Forward PE Ratio
434.78
106.83
46.39
48.30
ONC vs MRNA, RPRX, ROIV: Forward PE Ratio Comparison
For the Biotechnology subindustry, BeOne Medicines's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BeOne Medicines Forward PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BeOne Medicines's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where BeOne Medicines's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
BeOne Medicines (ONC) has a Forward PE Ratio of 47.23 as of Jul. 18, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on BeOne Medicines and its competitors. According to the industry distribution chart, BeOne Medicines ranks #260 out of 354 companies in the Biotechnology industry, placing it in the top 73.4%.
Is BeOne Medicines' Forward PE Ratio too high?
BeOne Medicines' current Forward PE Ratio is 47.23. The Biotechnology industry median Forward PE Ratio is 21.97. BeOne Medicines' value of 47.23 is 115% above this industry median. Based on the distribution chart, BeOne Medicines ranks #260 out of 354 companies in the Biotechnology industry, which is below the industry midpoint. Overall, BeOne Medicines has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BeOne Medicines' Forward PE Ratio compare to MRNA and RPRX?
According to the Biotechnology industry distribution chart, BeOne Medicines ranks #260 out of 354 companies for Forward PE Ratio. This places BeOne Medicines in the lower half of its industry. The industry median Forward PE Ratio is 21.97. BeOne Medicines' value of 47.23 is 115% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Biotechnology company?
The median Forward PE Ratio among Biotechnology companies is 21.97, based on 354 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BeOne Medicines's current Forward PE Ratio of 47.23 is 115% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on BeOne Medicines and its competitors. For the Biotechnology industry, the median Forward PE Ratio is 21.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BeOne Medicines's current Forward PE Ratio is 47.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BeOne Medicines stock overvalued right now?
Based on GuruFocus' analysis, BeOne Medicines (ONC) is currently considered Modestly Undervalued. The stock's GF Value™ is $369.74, compared to a current price of $312.02 — trading 15.6% below its estimated fair value. The current Forward PE Ratio is 47.23 and 115% above the Biotechnology industry median of 21.97. BeOne Medicines' overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For BeOne Medicines (ONC), the current Forward PE Ratio is 47.23 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BeOne Medicines (ONC) Overvalued in 2026?
Based on GuruFocus' analysis, BeOne Medicines stock appears to be undervalued.
The current stock price of $312.02 is trading 15.6% below its estimated GF Value™ of $369.74.
GuruFocus considers BeOne Medicines to be Modestly Undervalued.
Key valuation signals for ONC:
Forward PE Ratio: 47.23
GF Value™: $369.74 vs. price of $312.02 (15.6% below fair value)
Industry Position: 115% above the Biotechnology median (#260 of 354)
No single metric tells the full story. See the ONC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
77GF Score
Get the complete analysis for ONC
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ONC has been successfully added to your 
